乳腺癌中CREPT的表达及临床意义

Expression and clinical significance of CREPT in breast cancer

目的探讨乳腺癌组织中CREPT的表达及与乳腺癌临床病理特征的相关性及临床意义。方法采用免疫组化EnVision两步法检测132例乳腺癌及52例癌旁乳腺组织中CREPT蛋白的表达,并分析其高表达与乳腺癌临床病理特征的关系。采用Western blot及qRT-PCR法检测12对新鲜乳腺癌组织及配对癌旁乳腺组织中CREPT蛋白及mRNA的表达。结果Western blot及qRT-PCR结果显示:乳腺癌组织中CREPT蛋白及mRNA高表达(P<0.01)。免疫组化结果显示:乳腺癌组织中CREPT的高表达为58%(76/132),显著高于癌旁乳腺组织(0,0/52),差异有统计学意义(P<0.01)。CREPT高表达与乳腺癌分型及有无淋巴结转移均有关(P<0.01),与患者性别、年龄、原发灶最大径均无关(P>0.05)。随访105例CREPT高表达者,其总生存期明显低于低表达者(P<0.05)。结论CREPT在乳腺癌组织中高表达,其与临床TNM分期、有无淋巴结转移相关;其有望成为乳腺癌分型的潜在生物学标志物及治疗的新靶点。

Purpose To investigate the expression of CREPT in breast cancer and its correlation with clinical pathological features and clinical significance in breast cancer.Methods The expression of CREPT in 132 cases of breast cancer and 52 cases of breast tissue adjacent to cancer was detected by immunohistochemistry of EnVision two-step method,and the relationship between its high expression and the clinical pathological characteristics of breast cancer was analyzed.Western blot and qRT-PCR were used to detect the expression of CREPT protein and mRNA in 12 pairs of fresh breast cancer tissues and paired adjacent breast tissues.Results Western blot and qRT-PCR showed that CREPT protein and mRNA were highly expressed in breast cancer tissues(P<0.01).Immunohistochemistry,the high expression of CREPT in breast cancer tissues was 58%(76/132),which was significantly higher than that in adjacent breast tissues(0,0/52).The difference was statistically significant(P<0.01).The high expression of CREPT was related to the classification of breast cancer and lymph node metastasis(P<0.01),but not to the gender,age and diameter of the primary lesion(P>0.05).The overall survival of 105 patients with high CREPT expression was significantly lower than that of patients with low CREPT expression(P<0.05).Conclusion High expression of CREPT in breast cancers and its associated with clinical TNM staging,lymph node metastasis,which suggesting CREPT is expected to become a potential biological marker for breast cancer typing and a new target for treatment.